MN-DIGI-INTERNATIONAL
Digi International®, (NASDAQ: DGII), a leading provider of Internet of Things (IoT) connectivity solutions, today expanded its Digi XBee® 3 Global Cellular family of solutions with the unveiling of Digi XBee® 3 Cellular LTE Cat 1 and Digi XBee® 3 Cellular LTE-M/NB-IoT smart modems for global deployment. These new modules deliver the power and flexibility of the renowned Digi XBee ecosystem — pre-certified for global cellular deployments to accelerate development times and eliminate the costs associated with carrier certification processes.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230314005045/en/
Digi XBee® 3 Cellular LTE Cat 1 and Digi XBee® 3 Cellular LTE-M/NB-IoT smart modems for global deployment unveiled at Embedded World 2023. (Graphic: Business Wire)
The newest additions to the Digi XBee Global Cellular family are dependable, compact solutions with BLE and end-device carrier certifications that can be used worldwide and are equipped with Global Navigation Satellite System (GNSS) positioning. They deliver simplified and future-proof solutions for developers and original equipment manufacturers (OEMs) looking to add reliable cellular IoT connectivity to their devices or IoT gateways. With pre-integrated certifications, the XBee 3 Global family supports LTE Cat 1, LTE-M and NB-IoT networks, with 2G/3G fallback — for applications that require reliable cellular connectivity, anywhere in the world. These solutions support low-power applications such as meters, smart sensors and other fixed assets that send small portions of data.
Digi XBee Global Cellular family smart modems are designed to be provisioned, managed and monitored by Digi Remote Manager® (Digi RM). Additionally, they support MicroPython programming, Bluetooth, GNSS positioning for geolocation and Digi TrustFence® security.
“Our Digi XBee 3 Global Cellular family expands the XBee ecosystem of RF modules, gateways, adapters and software — giving OEMs access to the smallest, pre-certified modems for cellular networks that will save thousands in development time and money,” said Steve Ericson, Vice President and General Manager of Digi’s OEM Solutions division. “Pre-certification, along with the integration of advanced software and security, and a full ecosystem of tools supports rapid time-to-market.”
Digi XBee 3 Global Cellular Cat 1
Designed for applications that require higher throughput, the XBee 3 Cat 1 smart modem gives customers a single SKU for deployment of cellular products anywhere in the world. It includes 2G/3G fallback for use in regions and countries where Cat 1 isn’t available.
Digi XBee 3 Global Cellular LTE-M/NB-IoT
Offering low-power cellular connectivity, Digi XBee 3 LTE-M/NB-IoT modules are designed for applications that require data collection from edge devices — supporting higher data rates, lower latency and cell tower handoff, making it ideal for mobile applications and asset tracking.
Delivering the lowest power consumption and data transfer rates available, NB-IoT is ideal for battery-powered and passive devices, which transmit small amounts of data at intermittent times.
All smart modems within the XBee Cellular family solution include MicroPython programming resources to enable direct custom scripting, 2G/3G fallback to ensure connectivity, GNSS for accurate location services, OTA firmware updates and access to Digi Remote Manager for over-the-air software updates and monitoring. With built-in Digi TrustFence® security, identity and data privacy features, customers can tap into more than 175 controls to protect against new and evolving cyber threats. The Digi XBee Mobile App and Digi XBee Studio® tool suite simplify setup, configuration and testing. Digi XBee Data Plans are also available for a wide variety of cellular connectivity requirements.
Digi XBee 3 Global Cellular Family solutions are available now. For more information, visit: https://www.digi.com/products/embedded-systems/digi-xbee/cellular-modems.
About Digi International
Digi International (NASDAQ: DGII) is a leading global provider of IoT connectivity products, services and solutions. It helps companies create next-generation connected products and deploy and manage critical communications infrastructures in demanding environments with high levels of security and reliability. Founded in 1985, Digi has helped customers connect more than 100 million things and counting. For more information, visit www.digi.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230314005045/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Seoul Semiconductor: Philips Lighting Products Ordered to Recall 7-Year-Old Items26.12.2024 08:00:00 CET | Press release
The German District Court of Düsseldorf, on November 19 ruled in favor of Seoul Semiconductor (KOSDAQ:046890) in the patent infringement lawsuits, and also ordered that products manufactured by Philips Lighting and sold since March 2017 be recalled and destroyed. The Court also ruled that a fine of up to €250,000 would be imposed for each violation of this order. On December 17, the German Federal Patent Court also affirmed the validity of these patents, which solidifies the strength of many related patents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225151382/en/ Application Examples with CRI 70 or Higher (Photo: Seoul Semiconductor) These court orders relate to the core technology used to achieve CRI 70 (Color Rendering Index 70%) or higher, applicable to all home lighting, automotive lighting products, IT flash, and backlights. Since the effects of these judgments are applicable to all products infringing on the pa
ispace-EUROPE and the Italian Space Agency (ASI) Sign Payload Services Agreement to Transport a Laser Retroreflector Array (LaRA2) on the Moon Surface26.12.2024 08:00:00 CET | Press release
Agreement Marks Significant Step Towards Increasing Italy’s Contribution to advancing Lunar Exploration ispace EUROPE S.A. (ispace-EUROPE), the Luxembourg-based subsidiary of ispace, inc., and the Italian Space Agency (ASI) have signed a payload services agreement to transport a Laser Retroreflector Array (LaRA2) to enable accurate position measurements on the Moon via laser ranging experiments, the two organizations announced today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225137548/en/ The shape of LaRA2, a palm-sized dome (Photo: Business Wire) The agreement marks the first full-scale contract between ispace-EUROPE and ASI, with both organizations looking to joint future lunar development. LaRA2 is a small, robust, and lightweight instrument built to work without any power source and to survive the harsh surface conditions on the Moon for an extended period of time. It features a precise array of retroreflectors
Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn24.12.2024 08:00:00 CET | Press release
Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) based on the TROPION-Lung01 phase 3 trial. The decision to withdraw the MAA was informed by feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA). Daiichi Sankyo and AstraZeneca will continue to work to bring datopotamab deruxtecan to patients with lung cancer in the EU who can benefit and are committed to unlocking the potential of this medicine in lung cancer through our robust clinical development program which includes seven pivotal trials in various lung cancer settings. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Dai
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 1323.12.2024 22:05:00 CET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational
Perma-Pipe International Holdings, Inc. Announces Third Quarter Financial Results23.12.2024 18:43:00 CET | Press release
The Company generated net sales of $41.6 million for the quarter and $113.4 million year-to-dateIncome before income taxes of $5.1 million for the quarter and $13.2 million year-to-dateBacklog of $114.2 million at October 31, 2024, compared to $68.5 million at January 31, 2024 Perma-Pipe International Holdings, Inc. (NASDAQ: PPIH) announced today financial results for the second quarter and fiscal year-to-date period ended October 31, 2024. "Net sales for the third quarter were $41.6 million, a decrease of $4.1 million, as compared to the same quarter last year. Net income attributable to common stock of $2.5 million was an increase of $0.5 million, or 29%, compared to $1.9 million in the third quarter of 2023. For the nine months ended October 31, 2024, net sales of $113.4 million represent an increase of 3% compared to the nine months ended October 31, 2023. The net income attributable to common stock of $7.2 million was an increase of $5.4 million, or 294%, compared to net income at
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom